- Home
- BWAY
BWAY
BrainsWay Ltd.
as 07-26-2024 4:00pm EST
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
| Founded: | 2003 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 102.2M | IPO Year: | 2019 |
| Target Price: | $13.00 | AVG Volume (30 days): | 45.0K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.25 - $8.25 | Next Earning Date: | 08-06-2024 |
| Revenue: | $34,255,000 | Revenue Growth: | 32.61% |
| Revenue Growth (this year): | 368.62% | Revenue Growth (next year): | 18.17% |
Latest BrainsWay Ltd. News
BWAY Breaking Stock News: Dive into BWAY Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Strength Seen in Brainsway (BWAY): Can Its 9.3% Jump Turn into More Strength?
GlobeNewswire
3 days ago
BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024
Zacks
a month ago
BrainsWay (BWAY) Inks Distribution Agreement to Expand Foothold
GlobeNewswire
a month ago
BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada
Zacks
a month ago
BrainsWay (BWAY) to Advance in DEEP TMS for MDD With New Trial
GlobeNewswire
2 months ago
BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression
MT Newswires
2 months ago
Brainsway's Deep Transcranial Magnetic Stimulation Gets Expanded FDA Labeling; Shares Rise
GlobeNewswire
2 months ago
BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression
Compare BWAY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BWAY BrainsWay Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.